Literature DB >> 23796731

Vascular effects of nonsteroidal antiinflammatory drugs.

Martin Soubrier1, David Rosenbaum, Zuzana Tatar, Clément Lahaye, Jean-Jacques Dubost, Sylvain Mathieu.   

Abstract

The effect of nonsteroidal antiinflammatory drugs (NSAIDs) on the risk of cardiovascular events remains controversial. Among NSAIDs, only low-dose aspirin exerts protective vascular effects. Low-dose aspirin has been proven effective for secondary prevention. For primary prevention, the usefulness of low-dose aspirin is debated, as illustrated by the differences in recommendations across countries. NSAIDs other than aspirin, whether COX-2 selective or nonselective, increase the risk of cardiovascular events. Among them, naproxen is associated with the smallest risk increase. In patients with a history of coronary artery disease, diclofenac seems to carry the greatest risk, but all NSAIDs should be avoided. Uncertainties persist about aspirin interactions with other NSAIDs and with proton pump inhibitors. An adverse effect of acetaminophen on the risk of cardiovascular disease cannot be completely ruled out.
Copyright © 2013 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Acetaminophen; Aspirin; Cardiovascular death; Myocardial infarction; Nonsteroidal antiinflammatory drugs; Stroke

Mesh:

Substances:

Year:  2013        PMID: 23796731     DOI: 10.1016/j.jbspin.2012.12.002

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  7 in total

Review 1.  Functional neural-bone marrow pathways: implications in hypertension and cardiovascular disease.

Authors:  Jasenka Zubcevic; Monica M Santisteban; Teresa Pitts; David M Baekey; Pablo D Perez; Donald C Bolser; Marcelo Febo; Mohan K Raizada
Journal:  Hypertension       Date:  2014-03-31       Impact factor: 10.190

2.  Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.

Authors:  Carolyn Bornstein; Marie Craig; Diane Tin
Journal:  Can Pharm J (Ott)       Date:  2014-03

Review 3.  Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations.

Authors:  Anne Tournadre; Sylvain Mathieu; Martin Soubrier
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-09-05       Impact factor: 5.346

Review 4.  Impairment of aspirin antiplatelet effects by non-opioid analgesic medication.

Authors:  Amin Polzin; Thomas Hohlfeld; Malte Kelm; Tobias Zeus
Journal:  World J Cardiol       Date:  2015-07-26

Review 5.  Rheumatoid arthritis in the elderly in the era of tight control.

Authors:  Martin Soubrier; Zuzana Tatar; Marion Couderc; Sylvain Mathieu; Jean-Jacques Dubost
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

Review 6.  Management of inflammatory rheumatic conditions in the elderly.

Authors:  Clément Lahaye; Zuzana Tatar; Jean-Jacques Dubost; Anne Tournadre; Martin Soubrier
Journal:  Rheumatology (Oxford)       Date:  2019-05-01       Impact factor: 7.580

7.  Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis.

Authors:  Erdinç Hatipsoylu; İlker Şengül; Taciser Kaya; Altınay Göksel Karatepe; Seniz Akçay; Leyla Isayeva; Giray Bozkaya; Erhan Tatar
Journal:  Anatol J Cardiol       Date:  2019-09       Impact factor: 1.596

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.